PCN46 Cost-Efficacy Analysis of Licensed Drugs for the Treatment of Metastatic Castrate Resistant Prostate Cancer Post Docetaxel Based on Hospital Drug Evaluation Methodology in Spain
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1239
https://www.valueinhealthjournal.com/article/S1098-3015(12)02952-X/fulltext
Title :
PCN46 Cost-Efficacy Analysis of Licensed Drugs for the Treatment of Metastatic Castrate Resistant Prostate Cancer Post Docetaxel Based on Hospital Drug Evaluation Methodology in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02952-X&doi=10.1016/j.jval.2012.08.1239
First page :
A417
Section Title :
Cancer
Open access? :
No
Section Order :
743